TER 930180

Drug Profile

TER 930180

Latest Information Update: 22 Nov 2007

Price : $50

At a glance

  • Originator Terumo
  • Class Antiallergics; Antithrombotics
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 09 Oct 2001 No-Development-Reported for Thrombosis in Japan (Unknown route)
  • 26 Aug 1997 A study has been added to the Thromboses pharmacodynamics section
  • 04 Dec 1995 Two animal studies have been added to the Thromboses pharmacodynamics and pharmacokinetics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top